Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Bank of Montreal Can

Bank of Montreal Can decreased its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 78.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 845,068 shares of the company’s stock after selling 2,988,111 shares during the period. Bank of Montreal Can’s holdings in Bausch Health Companies were worth $6,823,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of BHC. Mountain Hill Investment Partners Corp. purchased a new stake in Bausch Health Companies during the 4th quarter worth approximately $56,000. Tobam lifted its position in Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after acquiring an additional 1,422 shares during the period. Norges Bank purchased a new stake in Bausch Health Companies during the 4th quarter valued at about $141,000. DGS Capital Management LLC acquired a new position in shares of Bausch Health Companies in the fourth quarter valued at about $143,000. Finally, Kendall Capital Management lifted its holdings in shares of Bausch Health Companies by 43.4% during the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock worth $145,000 after purchasing an additional 5,445 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of recent research reports. Royal Bank of Canada reduced their price target on shares of Bausch Health Companies from $9.00 to $8.50 and set a “sector perform” rating for the company in a research report on Monday, April 7th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.17.

Bausch Health Companies Stock Performance

Shares of NYSE BHC opened at $4.33 on Monday. The company has a market capitalization of $1.59 billion, a PE ratio of -36.04, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43. The company’s fifty day moving average price is $6.53 and its 200 day moving average price is $7.53. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.51 billion. On average, equities analysts expect that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.